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ABSTRACT
BACKGROUND: Mobile Health technology for the management of patients with atrial fibrillation is unknown.
METHODS: The simple mobile AF (mAF) App was designed to incorporate clinical decision-support tools
(CHA2DS2-VASc [Congestive heart failure, Hypertension, Age ≥75 years, Diabetes Mellitus, Prior Stroke
or TIA, Vascular disease, Age 65–74 years, Sex category], HAS-BLED [Hypertension, Abnormal renal/
liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly],
SAMe-TT2R2 [Sex, Age <60 years, Medical history, Treatment, Tobacco use, Race] scores), educational
materials, and patient involvement strategies with self-care protocols and structured follow-up. Patients with
atrial fibrillation were randomized into 2 groups (mAF App vs usual care) in a cluster randomized design
pilot study. Patients’ knowledge, quality of life, drug adherence, and anticoagulation satisfaction were evalu-
ated at baseline, 1 month, and 3 months. Usability, feasibility, and acceptability of the mAF App were assessed
at 1 month.
RESULTS: A total of 113 patients were randomized to mAF App intervention (mean age, 67.4 years; 57.5%
were male; mean follow-up, 69 days), and 96 patients were randomized to usual care (mean age, 70.9 years;
55.2% were male; mean follow-up, 95 days). More than 90% of patients reported that the mAF App was
easy, user-friendly, helpful, and associated with significant improvements in knowledge compared with the
usual care arm (P values for trend <.05). Drug adherence and anticoagulant satisfaction were significantly
better with the mAF App versus usual care (all P < .05). Quality of life scores were significantly increased
in the mAF App arm versus usual care, with anxiety and depression reduced (all P < .05).
CONCLUSIONS: The pilot mAFA Trial is the first prospective randomized trial of Mobile Health technolo-
gy in patients with atrial fibrillation, demonstrating that the mAF App, integrating clinical decision support,
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education, and patient-involvement strategies, significantly improved knowledge, drug adherence, quality
of life, and anticoagulation satisfaction.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/). • The American Journal of Medicine (2017) 130,
1388–1396
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INTRODUCTION
Atrial fibrillation is the most common cardiac arrhythmia,
with a global health burden of approximately 33.5 million
individuals with atrial fibrillation worldwide.1 The lifetime
risk for developing atrial fibrillation is 21% to 23% in
women and 17% to 26% in men.2-4 In the past 5 decades,
age-adjusted atrial fibrillation
prevalence globally has increased
5-fold5 and is expected to double by
2050.1 Atrial fibrillation–related
stroke is devastating, which has
been described as an “atrial
fibrillation–related stroke tsunami”
without proper treatment with oral
anticoagulants.6
The underuse or inappropriate
use of oral anticoagulants is
common in the population with
atrial fibrillation, particularly so in
many Asian countries.7 Even in the
new era of non–vitamin K antago-
nist oral anticoagulants,5 many
patients remain undertreated.8 Also,
28% of high-risk patients (defined
as a CHA2DS2-VASc [Congestive
heart failure, Hypertension, Age ≥75
years, Diabetes Mellitus, Prior
Stroke or TIA, Vascular disease,
Age 65–74 years, Sex category]
score ≥2) are not anticoagulated, whereas 51% of very low-
risk patients are inappropriately anticoagulated.9
Nonadherence to atrial fibrillation guidelines is common
across all risk strata, ranging from 33% to 68% among the
high-risk population.10 On the other hand, patients’ prefer-
ences are another important reason for nonadherence to
therapy.11 Thus, efforts to streamline decision-making for stroke
prevention in patients with atrial fibrillation and to improve
patients’ knowledge are important in the era of non–vitamin
K antagonist oral anticoagulants.12
Novel strategies that incorporate eHealth or Mobile Health
encompass the use of information and communication tech-
nologies in the management of disease, providing innovative
solutions to the problem of long-term management after
discharge.13,14 However, there are limited data on the imple-
mentation of Mobile Health technology for the management
of patients with atrial fibrillation, particularly in relation to
its feasibility, efficacy, and safety.
Our aim was to perform a randomized, controlled trial
(mAFA; Clinical Trials Registry Number: ChiCTR-IOR-
17010436) of a Mobile Health technology–supported atrial
fibrillation management model, integrating clinical decision
support tools, guideline-based treatment, and patient involve-
ment. The mAFA Trial is the first prospective randomized trial
of Mobile Health technology in pa-
tients with atrial fibrillation.
MATERIALS AND METHODS
A user-friendly mAF App was devel-
oped for smart phones based on the
Android Operating System (Google
Inc., Mountain View, Calif) andApple
iOS (Cupertino, Calif), which incor-
porated clinical decision support
(clinical risk scores, ie, CHA2DS2-
VASc, HAS-BLED [Hypertension,
Abnormal renal/liver function, Stroke,
Bleeding history or predisposition,
Labile INR, Elderly, Drugs/alcohol
concomitantly], and SAMe-TT2R2
[Sex,Age < 60 years, Medical history,
Treatment, Tobacco use, Race] score),
patient educational programs, patient
involvement self-care components,
and structured follow-up components.
Patients with atrial fibrillation
were randomized to 2 groups (mAF App vs usual care) in a
cluster randomized design based in 2 hospitals, Chinese PLA
General Hospital and Meishan City People’s Hospital, between
January 1, 2017, and May 1, 2017. Inclusion criteria in-
cluded adult patients aged >18 years with atrial fibrillation
diagnosed with electrocardiogram and 24-hour Holter. We ex-
cluded individuals aged <18 years, those with valvular atrial
fibrillation (eg, prosthetic), and those unable to provide written
informed consent (Supplementary Figure 1, available online).
Patients’ knowledge, quality of life, drug adherence, and
anticoagulation satisfaction were evaluated at baseline, 1
month, and 3 months. Usability, feasibility, and acceptabil-
ity of the mAF App were assessed at 1 month.
Design of mAF App
The mAF App was designed with versions for patients and
doctors respectively. The mAF App incorporates details such
CLINICAL SIGNIFICANCE
• Mobile Health technology is increasing-
ly proposed for cardiovascular disease
management.
• The feasibility, efficacy, and safety
of Mobile Health technology for the
management of patients with atrial fi-
brillation are unknown.
• The pilot mAFA Trial demonstrated that
an approach integrating clinical deci-
sion support, education, and patient-
involvement strategies using the mAF
App would translate to significantly im-
proved knowledge, drug adherence,
anticoagulant satisfaction, and quality
of life.
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as the Personal Health Record, stroke and bleeding risk as-
sessment (CHA2DS2-VASc and HAS-BLED scores,
respectively), and a clinical score to aid warfarin control pre-
diction (SAMe-TT2R2), patient educational programs, patient
involvement self-care items, and structured follow-up
components.
Personal Health Record. The mAF App could record atrial
fibrillation features, patient medical history, laboratory tests,
atrial fibrillation treatments, antithrombotic drugs, and other
pharmacologic treatments at baseline. Patients were recom-
mended to upload their laboratory tests (eg, hemoglobin,
platelet count, liver/renal function tests, blood lipids), elec-
trocardiogram, and echocardiogram (if available) at 1 month
and 3 months after their initial consultation.
Clinical Decision Support. The mAF App automatically cal-
culates CHA2DS2-VASc, HAS-BLED, and SAMe-TT2R2
scores after the patient’s Personal Health Record is com-
pleted (Supplementary Figure 2, available online).
Patients with a low stroke risk (CHA2DS2-VASc score 0
in men, 1 in women) were recommended no antithrombotic
treatment. Patients at moderate stroke risk (1 stroke risk
factor) were suggested to consider oral anticoagulants bal-
ancing against bleeding risk, and those at high stroke risk
(CHA2DS2-VASc ≥2) were recommended oral anticoagu-
lants. Patients with HAS-BLED ≥3 were flagged for follow-
up, and modifiable bleeding risk factors were proactively
addressed. Because non–vitamin K antagonist oral antico-
agulants are “self-pay” drugs and not reimbursed in China,
if the patients had a SAMe-TT2R2 score 0 to 2, they were con-
sidered to receive warfarin treatment. If the SAMe-TT2R2 score
was >2, the patients would have additional education/
counseling about warfarin and more regular review/
international normalized ratio checks, or to use a non–
vitamin K antagonist oral anticoagulant.
Patient’s Educational Program. There were 8 compo-
nents of the patient’s educational program, with additional
patient self-support items. Patients followed the educational
program on their mobile device to improve their knowledge
of atrial fibrillation and learn how to manage themselves at
home (Supplementary Figure 3, available online). Patients’
knowledge and understanding were assessed at baseline, 1
month, and 3 months using a 11-item questionnaire regard-
ing atrial fibrillation.15
Patient Involvement with Self-Care. The patients were en-
couraged to monitor their heart rate and blood pressure,
and feedback on their treatment using the mAF App
(Supplementary Figure 4, available online). Their quality of
life was assessed using the Euro EQ-5D-Y at baseline, 1
month, and 3 months.
Structured Follow-Up. Structured follow-up was planned
at 1, 3, 6, 9, and 12 months after consultation/discharge, and
included assessment of drug therapy, thrombotic events, bleed-
ing events, quality of life, oral anticoagulant satisfaction, and
mAF App investigations (Supplementary Figure 5, avail-
able online). A reminder “alert” was sent automatically to
patients 1 week before and after the follow-up time-point by
the mAF App.
The patients’ drug adherence was assessed at baseline, 1
month, and 3 months with the Pharmacy Quality Alliance ad-
herence measure, with a 3-item Adherence Estimator.16 The
Anti-Clot Treatment Scale was adapted to evaluate the sat-
isfaction of patients with oral anticoagulants in this Chinese
population with atrial fibrillation (Supplementary Table 1,
available online).
Data Management, Quality Control, Data
Security, and Ethics
Users had a user-sensitive password for access to their mAF
App. Personal Health Records were stored as structured data
on a cloud platform. For example, the medical records and
laboratory tests could be uploaded to mAF App as image files,
and then the image files were transferred into structured data
with optical character recognition technology. Two persons
independently double checked the structured data and the
source documentation (ie, the image files of laboratory tests
and medical records) for consistency and accuracy to achieve
good-quality control of data management.
Health Insurance Portability and Accountability Act re-
quirements were adopted to confirm data security during data
transfer and data storage, in terms of the Administrative Pro-
cedures, Physical Safeguards, Technical Security Services, and
Technical Security Mechanisms. Data input into analysis was
performed by 2 individuals, who were blinded for the inter-
vention groups. Data were double checked independently by
a third investigator. Patient records and information were
anonymized and de-identified before analysis.
The Medical Ethics Committee of PLA General Hospital
and the China Food and Drug Administration (Registry
Number: XZF20120145) approved the present study proto-
col (Approval Number: S2016-086-01). The present study was
registered in the Chinese Clinical Trial Registry, Internation-
al Clinical Trials Registry Platform of the World Health
Organization (ChiCTR-IOR-17010436).
Statistical Analysis
Continuous variables were tested for normality by the
Kolmogorov–Smirnov test. Data with a normal distribution
are presented as a mean (standard deviation) and analyzed
using the t test. Data with a non-normal distribution are pre-
sented as median (interquartile range). The comparison of
discrete variables was performed using the chi-square test.
The usability, feasibility, and acceptability of the mAF App
were investigated at 1 month, and the satisfaction rate was
calculated. Data on patients’ knowledge, quality of life scores,
antithrombotic drugs, and other drugs at the 3 time-points
(baseline, 1 month, and 3 months) were presented graphi-
cally to illustrate the change in these variables over time
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between the mAF App and usual care groups. Trends of im-
provement of patients’ knowledge at baseline, 1 month, and
3 months were analyzed with Cochran’s and Mantel–Haenszel
statistics.
Patients’ adherence to drug therapy was calculated using
the 3-item Adherence Estimator scores, comparing patients
with usual care and mAF App, and was analyzed with the
Mann–Whitney U test.
Comparative analysis of Anti-Coagulation Satisfaction and
Quality of Life questionnaire scores (EuroQol, EQ-5D-Y)
between patients with usual care and the mAF App was per-
formed using t tests, and the chi-square test was used for
comparisons of improvement of mobility, self-care, usual ac-
tivities, pain/discomfort, and anxiety/depression at baseline,
1 month, and 3 months.
A sample size of 112 patients (56 in each group) allows
for a 20% attrition rate in the completion of the question-
naires and would have at least 80% power to detect an 18.5%
increase in knowledge about the condition between base-
line and follow-up.17 A beta = 0.20 and alpha = 0.05 were
assumed.
A P value <.05 was considered statistically significant. The
95% confidence intervals were calculated on the basis of
Poisson distribution. Statistical analysis was performed using
IBM SPSS Statistics version 21.0 (SPSS, Inc, Chicago, Ill).
RESULTS
In a cluster randomization design, 113 patients were ran-
domized to mAF App intervention (mean age, 67.4 years;
57.5% were male) with a mean follow-up of 69 days, whereas
96 patients were randomized to usual care (mean age, 70.9
years; 55.2% were male) with a mean follow-up of 95 days.
Of the original cohort, 113 patients with the mAF App had
a 1-month follow-up and 71 patients finished the 3-month
follow-up; 96 patients with usual care had 1-month and
3-month follow-up visits.
Hypertension, coronary artery disease, diabetes, and heart
failure were the most common comorbidities in both groups
(Table 1). The patients with the mAF App had more prior
atrial fibrillation ablation therapy (P = .036).
Usability, Feasibility, Acceptability of the
mAF App
More than 90% of patients agreed that the mAF App was easy,
user-friendly, and helpful, and they had good feedback with
the doctors on the mAF App (Supplementary Figure 6, avail-
able online).
Patients’ Knowledge on Atrial Fibrillation
Patients’ knowledge was improved greatly in those with the
mAF App over time (all P < .05), whereas this was not ob-
served in the patients with usual care (Figure 1).
Quality of Life Improvement in Patients with
the mAF App
Quality of life scores were significantly increased in the mAF
App arm compared with usual care at baseline and 1 and 3
Table 1 Baseline Characteristics
mAF App
(n = 113)
Usual Care
(n = 96) P Value
Age, y, mean (SD) 67.4 (10.6) 70.9 (17.4) .066
Male, n (%) 65 57.5% 53 55.2% .737
Medical history
Hypertension, n (%) 71 62.8% 51 53.1% .156
CAD, n (%) 50 44.2% 42 43.8% .942
Diabetes mellitus, n (%) 21 18.6% 14 14.6% .440
Heart failure, n (%) 14 12.4% 18 18.8% .203
Prior stroke, n (%) 9 8.0% 9 9.5% .717
PAD, n (%) 8 7.1% 3 3.1% .202
Renal dysfunction, n (%) 8 7.1% 5 5.2% .577
Hypertrophic cardiomyopathy, n (%) 5 4.4% 1 1.0% .144
Liver dysfunction, n (%) 4 3.5% 1 1.0% .239
AF treatment
AF ablation, n (%) 12 10.6% 3 3.1% .036
Dual-chamber pacemaker, n (%) 7 6.2% 4 4.2% .513
Pharmacologic cardioversion, n (%) 3 2.7% 2 2.1% .788
Electrical cardioversion, n (%) 0 0.0% 2 2.1% .123
LAAO, n (%) 1 0.9% 1 1.0% .908
CHA2DS2-VASc score 2.6 (1.5) 2.7 (1.6) .383
HAS-BLED score 1.4 (0.9) 1.6 (0.8) .053
AF = atrial fibrillation; CAD = coronary artery disease; CHA2DS2-VASc = Congestive heart failure, Hypertension, Age ≥75 years, Diabetes Mellitus, Prior
Stroke or TIA, Vascular disease, Age 65–74 years, Sex category; HAS-BLED = Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or pre-
disposition, Labile INR, Elderly, Drugs/alcohol concomitantly; LAAO = left atrial appendage occlusion; mAF App = mobile AF App; PAD = peripheral arterial
disease; SD = standard deviation.
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months (all P < .05) (Figure 2). Self-care improved signifi-
cantly over time with the mAF App, but not in usual care (all
P < .05). Anxiety and depression also tended to be amelio-
rated for patients using the mAF App compared with usual
care over time (all P < .05) (Table 2).
Drug Adherence to Therapy
Compared with patients with usual care, drug adherence was
significantly better with the mAF App at 1 month and 3 months
(all P < .05) (Table 3). Patients with the mAF App were more
likely to receive non–vitamin K antagonist oral anticoagu-
lants, ranging from 40.7% to 44.2%, compared with those
with usual care (P < .001). There was a slight increase in non–
vitamin K antagonist oral anticoagulant use (3.52%) over time
in patients using the mAF App (Figure 3). Secondary pre-
vention of comorbidities for atrial fibrillation was improved
in patients with the mAF App compared with patients with
usual care (Supplementary Figure 7, available online).
Anticoagulation Satisfaction
Patients with usual care expressed more anticoagulant
“burden,” whereas patients with the mAF App reported more
anticoagulant “benefit” (all P < .05) (Table 4).
DISCUSSION
To our knowledge, the mAFA Trial is the first prospective ran-
domized trial of Mobile Health technology in patients with
atrial fibrillation, demonstrating that the mAF App, integrating
clinical decision support, education, and patient-involvement
strategies, significantly improved knowledge, drug adher-
ence, quality of life, and anticoagulation satisfaction.
Clinical decision support provided by the mAF App stream-
lined guideline-based decision-making for stroke prevention
in patients with atrial fibrillation and was easily handled by
doctors and understood by patients. The clinical decision
support tools in the mAF App automatically assessed stroke
and bleeding risk, and stratified the patients with high-risk
stroke/thromboembolism to anticoagulant treatment, while bal-
ancing the bleeding risk. Bleeding risk factors were labeled
and could be reviewed by doctors and patients. Personal-
ized choice of oral anticoagulants would be advised on the
basis of the SAMe-TT2R2 score, resulting in rational decision-
making on anticoagulant management options.
Suboptimal thromboprophylaxis in patients with atrial fi-
brillation is highly prevalent, contributed to by an inappropriate
evaluation of the risks versus benefits of oral anticoagu-
lants, despite various guidelines on atrial fibrillation
management.18,19 Indeed, guideline-adherent antithrombotic
management is associated with significantly better outcomes.20
One barrier to adherence to guideline-optimized therapy could
be the challenges of a “real-world” busy clinical practice, and
the clinical decision-making tool in the mAF App could make
the process of guideline implementation easier.
To help access to guidelines for the clinician, a pocket
guideline App for European guidelines has been developed.
Figure 1 Patients’ knowledge of atrial fibrillation with usual care and mAF App at baseline, 1 month, and 3 months.
*P for trend <.05 at baseline, 1 month, and 3 months after discharge.
Figure 2 Time trends for quality of life scores of patients with
the mAF App. *Quality of life questionnaire was cited from the
EuroQol. Compared with patients with usual care, patients with
the mAF App, P < .05.
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The CATCH-ME treatment manager is integrated into the atrial
fibrillation section, but has yet to be prospectively tested or
evaluated.21 Another option is the Atrial Fibrillation Deci-
sion Support Tool, which is a patient-specific decision analytic
model composed of a 29-state Markov simulation, using in-
formation from the Electronic Health Record to integrate
patient-specific risk factors for stroke and hemorrhage in its
calculations.22 However, the intervention with the Atrial
Fibrillation Decision Support Tool did not result in signifi-
cant improvements in discordant antithrombotic therapy in
a population with atrial fibrillation.23 Other Apps have been
developed to provide stroke and bleeding risk calculations;
for example, the Computerised Antithrombotic Risk Assess-
ment Tool Version 2 could calculate the CHADS2 (Congestive
heart failure, Hypertension, Age over 75 years, Diabetes
Mellitus, Stroke), CHA2DS2-VASc, HAS-BLED, and
HEMORR2-HAGES (Hepatic or renal disease, Ethanol abuse,
Malignancy, Older age, Reduced platelet count or function,
Rebleeding risk, Hypertension, Anemia, Genetic factors, Ex-
cessive fall risk, Stroke) scores.24 Another clinical decision
support tool, which could calculate the CHA2DS2-VASc score
and alter the clinician prescription of oral anticoagulants
therapy, is being studied.25 However, these Apps/tools are
focused on doctors and not the follow-up and day-to-day man-
agement of patients with atrial fibrillation.
The mAF App not only calculates the clinical risk scores
but also automatically makes a follow-up plan, permitting the
patient’s self-monitoring and timely feedback. We also show
that the mAF App–based self-monitoring and feedback en-
hanced compliance and adherence to drug therapy and
Table 2 Quality of Life Questionnaire Responses in Patients with mAF App and Usual Care*
On Discharge
P Value
1 Month After Discharge
P Value
3 Months After Discharge
P ValuemAF App Usual Care mAF App Usual Care mAF App Usual Care
Mobility (n = 113) (n = 96) (n = 113) (n = 96) (n = 71) (n = 96)
No problems 70.80% 26.04% <.001 76.36% 26.04% <.001 77.46% 27.08% <.001
Slight problems 23.89% 32.29% .180 15.45% 35.42% .001 15.49% 36.46% <.001
Moderate problems 5.31% 31.25% <.001 7.27% 31.25% <.001 5.63% 29.17% <.001
Severe problems - 5.21% .014 - 2.08% .123 - 2.08% .221
Unable to walk about - 5.21% .014 0.91% 5.21% .062 1.41% 5.21% .062
Self-care
No problems 77.88% 55.21% <.001 83.64% 65.63% <.001 87.32% 68.75% <.001
Slight problems 18.58% 21.88% .449 15.45% 15.63% .908 11.27% 11.46% .272
Moderate problems 1.77% 9.38% <.001 - 8.33% .002 - 9.38% .001
Severe problems 1.77% 4.17% .301 - 2.08% .123 - 2.08% .221
Unable to wash or dress - 9.38% .001 0.91% 8.33% .008 1.41% 8.33% .008
Usual activities
No problems 69.91% 37.50% <.001 78.18% 45.83% <.001 77.46% 53.13% <.001
Slight problems 27.43% 30.21% .659 20.00% 27.08% .252 19.72% 18.75% .203
Moderate problems 2.65% 19.79% <.001 0.91% 16.67% <.001 1.41% 16.67% .001
Severe problems - 3.13% .001 - 2.08% .123 - 3.13% .133
Unable to do usual activities - 9.38% .001 0.91% 8.33% .008 1.41% 8.33% .050
Pain/discomfort
No pain or discomfort 63.70% 35.42% <.001 59.09% 41.67% .016 63.38% 40.63% .006
Slight pain or discomfort 25.66% 39.58% .046 33.64% 41.67% .231 25.35% 45.83% .007
Moderate pain or discomfort 10.62% 20.83% .041 6.36% 12.50% .114 9.86% 10.42% .906
Severe pain or discomfort - 1.04% .277 0.91% 2.08% .468 1.41% 1.04% .829
Extreme pain or discomfort - 3.13% .058 - 2.08% .123 - 2.08% .221
Anxiety/depression
Not anxious or depressed 50.44% 52.08% .831 62.70% 62.50% .935 57.75% 61.46% .629
Slightly anxious or depressed 40.71% 21.88% .005 31.82% 19.79% .048 32.39% 20.83% .091
Moderately anxious or depressed 8.85% 20.83% .014 5.45% 14.58% .023 9.86% 14.58% .363
Severely anxious or depressed - - - - - - - 1.04% .388
Extremely anxious or depressed - 5.21% .013 - 3.13% .058 - 2.08% .221
mAF App = mobile AF App.
*Quality of Life questionnaire was cited from the EuroQol.
Table 3 Drug Adherence at Baseline, 1 Month, and 3 Months*
mAF App Usual Care P Value
Baseline n = 113 n = 96
4 (4-11) 4 (4-11) .870
1 mo n = 113 n = 96
0 (0-4) 4 (0-11) <.001
3 mo n = 71 n = 96
2 (0-4) 4 (0-11) <.001
mAF App = mobile AF App.
*Pharmacy Quality Alliance adherence measures: 3-item Adherence
Estimator. Low risk = score of 0, moderate risk = score of 2-7, and high
risk = score of 8-36.
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anticoagulant satisfaction. With the planned follow-up by the
mAF App, the clinician receives the patient’s updated clin-
ical condition, reevaluates the patient’s clinical risk profile
(especially because stroke and bleeding risks are not static),
and regulates the dosage and use of various drugs. Mean-
while, patients have their questions clarified, become involved
in their self-management, and benefit overall from their treat-
ment plan.
Clinical follow-up ensures effective and safe anticoagu-
lant therapy in patients with atrial fibrillation. A systematic
review of drug adherence, thromboembolism, bleeding events,
any adverse effects, renal or hepatic function, and so forth,
is recommended for non–vitamin K antagonist oral
anticoagulants,26,27 although anticoagulation tests are not
needed. In one study, approximately two thirds of practitio-
ners adhered to recommendations on clinical and blood test
(creatinine and hemoglobin) follow-ups.28 Clinical risk moni-
toring is important, particularly for bleeding risk management
after discharge/prescription of non–vitamin K antagonist oral
anticoagulants, and the mAF App allows a practical tool to
monitor the patient’s clinical risk profile in “real time” al-
lowing a dynamic assessment (and reassessment) of patient
risks and changes over time. Moreover, the educational pro-
grams provided by the mAF App improved atrial fibrillation–
related knowledge and patient’s quality of life. Patient anxiety
and depression also were attenuated.
Contemporary atrial fibrillation clinical guidelines advocate in-
corporation of patient preferences for treatment and support, as
well as patient engagement in management decisions.21,29 None-
theless, patient beliefs and misconceptions about their treatment
and atrial fibrillation could affect their ability and willing-
ness to adhere to treatment recommendations.29 A prior study
Figure 3 Antithrombotic treatment in patients with the mAF App and usual care at baseline, 1 month, and 3 months after discharge. A,
Usual care. B, mAF App.
Table 4 Anticoagulation Satisfaction in Patients with mAF App and Usual Care*
Usual Care (n = 46) mAF App (n = 65) P Value
Baseline
Burden Scale, mean (SD) 20.83 (6.61) 17.58 (8.10) .028
Benefit Scale, mean (SD) 13.31 (3.39) 14.11 (3.65) .256
1 mo Usual care (n = 44) mAF App (n = 63) P
Burden Scale, mean (SD) 19.40 (6.05) 16.04 (7.50) .018
Benefit Scale, mean (SD) 14.19 (3.18) 15.09 (2.38) .013
3 mo Usual care (n = 45) mAF App (n = 42) P
Burden Scale, mean (SD) 19.30 (6.39) 15.57 (6.57) .008
Benefit Scale, mean (SD) 14.21 (3.37) 15.60 (2.73) .052
mAF App = mobile AF App; SD = standard deviation.
*Compared with the patients with usual care, P < .05. The Anti-Clot Treatment Scale was adapted to evaluate the satisfaction of patients with anti-
coagulant therapy in this Chinese population with atrial fibrillation. The adapted Anti-Clot Treatment Scale included a 15-item questionnaire, comprising
11 burden items and 4 benefit items. For every question, there are 5 item responses: “1, not at all” was calculated as 1 points; “2, a little” was calculated
as 2 points; “3, moderately” was calculated as 3 points; “4, quite a bit” was calculated as 4 points; and “5, extremely” was calculated as 5 points.
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has confirmed that a bespoke education intervention signifi-
cantly improved anticoagulation control of warfarin.30 A higher
patient education level has been associated with non–
vitamin K antagonist oral anticoagulant selection.31 The mAF
App provides the specific educational components, in terms
of warfarin, non–vitamin K antagonist oral anticoagulants,
and specific conditions, that may help patients with
self-management.
Study Limitations
Some limitations of this study need to be addressed. This was
a clustered randomized study, and a selection bias could exist;
however, the distribution of comorbidities between the mAF
App and the usual care arms were not significantly differ-
ent. Moreover, the clinician’s preference for oral anticoagulants
may have contributed to a higher rate of non–vitamin K an-
tagonist oral anticoagulant use in the mAF App group. The
educational program could have made the patients more aware
and thus be more likely to receive non–vitamin K antago-
nist oral anticoagulants. Finally, the impact on the clinical
outcomes (stroke, death, bleeds) of the mAF App needs to
be ascertained in a long-term prospective study with clini-
cal outcome data, which was not the principal objective of
the present study.
Despite these limitations, the present study still shows that
the clinical decision support, evidence-based clinical follow-
up, and patients’ involvement in self-care can help clinical
management for the population with atrial fibrillation, high-
lighting for the first time an effective Mobile Health–
support management strategy in such patients.
CONCLUSIONS
The pilot mAFA Trial is the first prospective randomized trial
of Mobile Health technology in patients with atrial fibrilla-
tion, demonstrating that an approach integrating clinical
decision support, education, and patient-involvement strate-
gies will translate to significantly improved knowledge, drug
adherence, anticoagulant satisfaction, and quality of life.
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APPENDIX
Supplementary Figure 1 Flow chart.
Supplementary Figure 2 Clinical decision support.
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Supplementary Figure 3 Patients’ educational program. *Patients followed the educational program
on their mobile device to improve their knowledge of atrial fibrillation and learn how to manage
themselves at home.
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Supplementary Figure 4 Patients’ involvement in self-care. *Patients could monitor their blood pressure and pulse rate, and be in-
volved in their management.
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Supplementary Figure 5 Structured follow-up in patients with
the mAF App. *The structured follow-up was planned at 1, 3, 6,
9, and 12 months after consultation/discharge, and included drug
therapy, thrombotic events, bleeding events, quality of life, anti-
coagulant satisfaction, and mAF App investigation. A reminder
alert was sent automatically to patients 1 week before and after
the follow-up time-point by the mAF App.
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Supplementary Figure 6 Usability, feasibility, and acceptability of the mAF App at 1 month. *A
total of 110 patients with the mAF App fulfilled the investigation.
Baseline (n=96)
Baseline (n=113) 1 month (n=110) 3 month (n=71)
1 month (n=96) 3 month (n=96)
Supplementary Figure 7 Drugs in patients with the mAF App and usual care at baseline, 1 month,
and 3 months. A, Usual care. B, mAF App. ACEI = angiotensin-converting enzyme inhibitor; ARB
= angiotensin receptor inhibitor; CCB = calcium channel blocker. Antiarrhythmic drugs: propafenone
and amiodarone. Glucose-lowering drugs: insulin, acarbose, glimepiride, and metformin. Other lipid-
lowering drugs: ezetimibe and probucol.
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Supplementary Table 1 Adapted Anticoagulant Satisfaction Questionnaire*
A
Not at All
B
A Little
C
Moderately
D
Quite a Bit
E
Extremely
1. How much does the possibility of bleeding as a result of
anticlot treatment limit you from taking part in vigorous
physical activities (eg, exercise, sports, dancing)?
1 2 3 4 5
2. How much does the possibility of bleeding as a result of
anticlot treatment limit you from taking part in your usual
activities (eg, work, shopping, housework)?
1 2 3 4 5
3. How bothered are you by the possibility of bruising as a result
of anticlot treatment?
1 2 3 4 5
4. How bothered are you by having to avoid other medicines (eg,
aspirin) as a result of anticlot treatment?
1 2 3 4 5
5. How much does anticlot treatment limit your diet (eg, food or
drink, including alcohol)?
1 2 3 4 5
6. How much of a hassle (inconvenience) are the daily aspects of
anticlot treatment (eg, remembering to take your medicine at a
certain time, taking the correct dose of your medicine)?
1 2 3 4 5
7. How much of a hassle (inconvenience) are the occasional
aspects of anticlot treatment (eg, the need for blood tests,
going to or contacting the clinic/doctor)?
1 2 3 4 5
8. How difficult is it to follow your anticlot treatment? 1 2 3 4 5
9. How much do you worry about your anticlot treatment? 1 2 3 4 5
10. How much of a burden is your anticlot treatment? 1 2 3 4 5
11. Overall, how much of a negative impact has your anticlot
treatment had on your life?
1 2 3 4 5
Total (scores)
A
Not at All
B
A Little
C
Moderately
D
Quite a Bit
E
Extremely
12. How confident are you that your anticlot treatment will protect
you from the stroke?
1 2 3 4 5
13. How safe do you feel because of your anticlot treatment? 1 2 3 4 5
14. How satisfied are you with your anticlot treatment? 1 2 3 4 5
15. Overall, how much of a positive impact has your anticlot
treatment had on your life?
1 2 3 4 5
Total (scores)
*“1, Not at all” was calculated as 1 points. “2, A little” was calculated as 2 points, “3, Moderately” was calculated as 3 points. “4, Quite a bit” was
calculated as 4 points. “5, Extremely” was calculated as 5 points.
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